Traitement hormonal delaménopause : oùenest-on en2013 ?
MISE AU POINT
24 | La Lettre du Rhumatologue • No 391 - avril 2013
Conclusion
Le THM est le traitement le plus effi cace pour amé-
liorer la qualité de vie des patientes ménopausées
souffrant de symptômes climatériques. De plus, ce
traitement est le plus adapté à la perte osseuse en
début de ménopause. Sa prescription repose sur
l’information des patientes, l’évaluation initiale puis
annuelle du rapport bénéfi ces/risques et le respect
des contre-indications. Les études actuelles, utili-
sant le THM tel qu’il est prescrit en France, avec des
estrogènes par voie transdermique associés à de la
progestérone naturelle ou à son dérivé, sont plutôt
rassurantes quant au risque vasculaire s’il est prescrit
après le début de la ménopause et pour des durées
courtes. ■
1. Rossouw JE, Anderson GL, Prentice RL et al. Risks and bene-
fi ts of estrogen plus progestin in healthy postmenopausal
women: principal results from the Women’s Health Initiative
randomized controlled trial. JAMA 2002;288(3):321-33.
2. Bath PM, Gray LJ. Association between hormone repla-
cement therapy and subsequent stroke: a meta-analysis.
BMJ 2005;330(7487):342.
3. Renoux C, Dell’aniello S, Garbe E, Suissa S. Transdermal
and oral hormone replacement therapy and the risk of stroke:
a nested case-control study. BMJ 2010;340:c2519.
4. Rossouw JE, Prentice RL, Manson JE et al. Postmenopausal
hormone therapy and risk of cardiovascular disease by age
and years since menopause. JAMA 2007;297(13):1465-77.
5. Hulley S, Grady D, Bush T et al. Randomized trial of
estrogen plus progestin for secondary prevention of coro-
nary heart disease in postmenopausal women. Heart and
Estrogen/progestin Replacement Study (HERS) Research
Group. JAMA 1998;280(7):605-13.
6. Løkkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH,
Agger C, Lidegaard Ø. Hormone therapy and risk of
myocardial infarction: a national register study. Eur Heart J
2008;29(21):2660-8.
7. Schierbeck LL, Rejnmark L, Tofteng CL et al. Effect of
hormone replacement therapy on cardiovascular events
in recently postmenopausal women: randomised trial. BMJ
2012;345:e6409.
8. Lewandowski KC, Komorowski J, Mikhalidis DP et al.
Effects of hormone replacement therapy type and route
of administration on plasma matrix metalloproteinases
and their tissue inhibitors in postmenopausal women. J Clin
Endocrinol Metab 2006;91(8):3123-30.
9. Le Gal G, Gourlet V, Hogrel P, Plu-Bureau G, Touboul PJ,
Scarabin PY. Hormone replacement therapy use is associated
with a lower occurrence of carotid atherosclerotic plaques
but not with intima-media thickness progression among
postmenopausal women. The vascular aging (EVA) study.
Atherosclerosis 2003;166(1):163-170.
10. Canonico M, Oger E, Plu-Bureau G et al. Hormone
therapy and venous thromboembolism among postmeno-
pausal women: impact of the route of estrogen adminis-
tration and progestogens: the ESTHER study. Circulation
2007;115(7):840-5.
11. Scarabin PY, Oger E, Plu-Bureau G. Differential asso-
ciation of oral and transdermal oestrogen-replacement
therapy with venous thromboembolism risk. Lancet
2003;362(9382):428-32.
12. Olié V, Plu-Bureau G, Conard J, Horellou MH, Cano-
nico M, Scarabin PY. Hormone therapy and recurrence of
venous thromboembolism among postmenopausal women.
Menopause 2011;18(5):488-93.
13. Gray S. Breast cancer and hormone-replacement
therapy: the Million Women Study. Lancet 2003;362(9392):
1332; author reply 1332.
14. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks
for breast cancer associated with different hormone repla-
cement therapies: results from the E3N cohort study. Breast
Cancer Res Treat 2008;107(1):103-11.
15. Chlebowski RT, Kuller LH, Prentice RL et al. Breast cancer
after use of estrogen plus progestin in postmenopausal
women. N Engl J Med 2009;360(6):573-87.
16. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk
in postmenopausal women using estradiol-progestogen
therapy. Obstet Gynecol 2009;113(1):65-73.
17. Anderson GL, Limacher M, Assaf AR et al. Effects of conju-
gated equine estrogen in postmenopausal women with
hysterectomy: the Women’s Health Initiative randomized
controlled trial. JAMA 2004;291(14):1701-12.
18. Wells G, Tugwell P, Shea B et al. Meta-analyses of thera-
pies for postmenopausal osteoporosis. V. Meta-analysis of
the effi cacy of hormone replacement therapy in treating
and preventing osteoporosis in postmenopausal women.
Endocr Rev 2002;23(4):529-39.
19. Briot K, Cortet B, Thomas T et al. 2012 update of French
guidelines for the pharmacological treatment of postmeno-
pausal osteoporosis. Joint Bone Spine 2012;79(3):304-13.
Références bibliographiques
AgendaAgenda
31e Journée de traumatologie du sport de la Pitié-Salpêtrière
Paris (Maison de la chimie), le 9 novembre 2013
L’objectif de cette journée organisée par J.Rodineau et S.Besch, de l’Association pour le développement de la recherche en traumatologie
dusport (ADRETS), est d’effectuer des mises au point sur les tendinopathies calcanéennes et rotuliennes.
Renseignement et inscription :
Cabinet médical (ADRETS)
206, avenue de Versailles, 75016 Paris.
E-mail : adrets@yahoo.fr